Cue Biopharma announced a private placement expected to close on July 13, 2026, raising approximately $50.0 million to support clinical development and general corporate purposes. Under a Securities Purchase Agreement, investors will acquire 1,418,071 common shares at $33.21 per share and pre-funded warrants for 87,500 shares at $33.209 per warrant, each with a $0.001 exercise price and cashless exercise. Concurrently, a Registration Rights Agreement commits the company to file a resale registration statement within 30 days of closing and maintain effectiveness until all registrable securities are sold. The financing includes investor ownership limits and customary conditions and indemnities.

Agreement 1: Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle

• Agreement type: Securities Purchase Agreement for private placement of equity
• Counterparty: Accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments
• Signed / Effective: Jul 09 2026 / Jul 13 2026
• Reason: Raise capital for clinical development and corporate needs

Agreement 2: Cue Biopharma Grants Investors Resale Registration Rights Following $50 Million Financing

• Agreement type: Registration Rights Agreement covering resale of securities
• Counterparty: Investors from the private placement
• Signed / Effective: Jul 09 2026 / Jul 13 2026
• Duration / Termination: Until all registrable securities are sold
• Reason: Provide resale liquidity to investors

Original SEC Filing: Cue Biopharma, Inc. [ CUE ] - 8-K - Jul. 10, 2026